Legacy Capital Wealth Partners LLC Acquires Shares of 1,320 Balchem Co. (NASDAQ:BCPC)

Legacy Capital Wealth Partners LLC purchased a new stake in shares of Balchem Co. (NASDAQ:BCPC) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,320 shares of the basic materials company’s stock, valued at approximately $232,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BCPC. Vanguard Group Inc. increased its position in Balchem by 3.8% during the first quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock worth $609,873,000 after buying an additional 144,423 shares during the last quarter. Conestoga Capital Advisors LLC raised its position in shares of Balchem by 1.8% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,175,569 shares of the basic materials company’s stock valued at $206,900,000 after acquiring an additional 20,360 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Balchem by 0.9% during the second quarter. Dimensional Fund Advisors LP now owns 697,461 shares of the basic materials company’s stock worth $107,372,000 after purchasing an additional 5,977 shares in the last quarter. Congress Asset Management Co. increased its stake in Balchem by 12.4% during the 3rd quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock worth $53,053,000 after purchasing an additional 33,373 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Balchem by 1.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 277,475 shares of the basic materials company’s stock valued at $42,717,000 after acquiring an additional 3,279 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. HC Wainwright increased their price target on Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th.

Balchem Stock Up 1.1 %

BCPC stock opened at $181.23 on Tuesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98. The business’s 50-day moving average is $172.20 and its two-hundred day moving average is $164.71. The company has a market cap of $5.89 billion, a price-to-earnings ratio of 48.72, a P/E/G ratio of 5.36 and a beta of 0.65. Balchem Co. has a fifty-two week low of $117.10 and a fifty-two week high of $186.03.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.